0001193125-22-282636.txt : 20221110 0001193125-22-282636.hdr.sgml : 20221110 20221110161757 ACCESSION NUMBER: 0001193125-22-282636 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20221110 FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Opthea Ltd CENTRAL INDEX KEY: 0001815620 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39621 FILM NUMBER: 221377487 BUSINESS ADDRESS: STREET 1: LEVEL 4 STREET 2: 650 CHAPEL STREET CITY: SOUTH YARRA, VICTORIA STATE: C3 ZIP: 3141 BUSINESS PHONE: 61 3 9826 0399 MAIL ADDRESS: STREET 1: LEVEL 4 STREET 2: 650 CHAPEL STREET CITY: SOUTH YARRA, VICTORIA STATE: C3 ZIP: 3141 6-K 1 d745307d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2022

Commission File Number: 001-39621

 

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

 

Level 4

650 Chapel Street

South Yarra, Victoria 3141

Australia

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

EXHIBITS

 

Exhibit   

Description

99.1    Press Release dated November 10, 2022

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    OPTHEA LIMITED
Date: November 10, 2022     By:  

/s/ Megan Baldwin

      Megan Baldwin, Ph.D.
      Chief Executive Officer and Managing Director
 EX-99.1 2 d745307dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

ASX, Nasdaq and Media Release

10 November 2022

Opthea to Present at Jefferies London Healthcare Conference

Melbourne, Australia; 10 November, 2022 – Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT (6:25 PM AEDT).

The live audio will be webcast and may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:

 

U.S.A. & International:    Australia:
Sam Martin    Rudi Michelson
Argot Partners    Monsoon Communications
Tel: +1 212 600 1902    Tel: +61 (0) 3 9620 3333
opthea@argotpartners.com   

Media:

Silvana Guerci-Lena

NorthStream Global Partners

Tel: +1 973 509 4671

silvana@nsgpllc.com

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399    Email: info@opthea.com    Web: www.opthea.com

GRAPHIC 3 g745307g1110112239156.jpg GRAPHIC begin 644 g745307g1110112239156.jpg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end